ArisGlobal is a leading global provider of innovative SaaS software solutions, which are transforming the way the most successful life sciences companies handle drug safety, clinical development, regulatory compliance, and medical affairs.
Company Background
- A visionary technology company that has successfully developed a next-gen platform, LifeSphere ®, using advanced cognitive computing and machine-learning.
- More than 500 life sciences companies, CROs and government health authorities rely on ArisGlobal’s software – to accomplish mission-critical tasks throughout the drug development process.
- Headquartered in the United States, with regional offices in Europe, India, Japan and China.
Vision & Outlook
- Support and accelerate growth to build a more sustainable world, through better environmental health, social equity and economic vitality.
- Invest in research and development, cognitive computing, global delivery, sustainable operations, and commercial excellence.
Highlights & Updates
- Nordic Capital acquired an additional stake from the founding family in 2021.
- In 2023, ArisGlobal acquired Amplexor Life Science, with the aim of creating the most comprehensive regulatory SaaS platform for the industry.
- In 2023, acquired SPORIFY, to integrate its application into the LifeSphere platform.
- Harnessing the power of generative AI to redefine industry standards, support R&D and drive innovation.
SECTOR
Technology & Payments
Healthcare
REVENUES 2023
EUR 130 million
EMPLOYEES
1,495
OWNERSHIP
Fund IX, Fund X
INVESTMENT DATE
2019
HEAD OFFICE
Waltham, MA, USA